DSGN - CIK 0001807120
The table below shows Design Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$54.36M | -$43.10M | -$58.56M | -$51.32M | -$29.38M | -$8.67M |
| Capital expenditure | $193.00K | $340.00K | $256.00K | $918.00K | $1.54M | $76.00K |
| Investing cash flow | $22.91M | $43.95M | $52.54M | -$220.99M | -$53.64M | -$33.56M |
| Dividends paid | - | - | - | - | - |
Design Therapeutics, Inc. reported operating cash flow of -$54.36M for fiscal year 2025. That is down 26.1% from -$43.10M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$8.67M (FY 2020) to -$54.36M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $25.74M | $513.00K | $724.00K | $235.00K | $379.21M | $44.53M |